

# Ekso Bionics to Submit 510(k) Notification in December

RICHMOND, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that Ekso Bionics recently met with FDA to discuss a change to the regulatory status of the Ekso robotic exoskeleton and other similar medical devices. Based on these discussions, the company made the decision to submit a 510(k) notification for the product in December. Ekso Bionics has been allowed to continue marketing the product while the 510(k) filing is under review. FDA is requiring Ekso Bionics to notify their customers of these changes in the form of a letter, which customers can expect to receive this week. Ekso Bionics is committed to full compliance with FDA's medical device regulations and is working with FDA to fully address the regulatory issues stemming from the recent change in classification for powered exoskeletons.

## ABOUT EKSO BIONICS

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product, called the Ekso device, has helped thousands of people with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at [www.eksobionics.com](http://www.eksobionics.com).

Facebook: [www.facebook.com/eksobionics](http://www.facebook.com/eksobionics)

Twitter: @eksobionics

YouTube: <https://www.youtube.com/user/EksoBionics/>

## FORWARD-LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be

realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at [www.eksobionics.com](http://www.eksobionics.com).

CONTACT: Media Contact:

Heidi Darling, Director of Marketing Communications

Phone: 415.302.4777

hdarling@eksobionics.com

Investor Contact:

Lauren Glaser, Vice President

Phone: 646.378.2972

lglaser@troutgroup.com

Source: Ekso Bionics